ExodusPoint Capital Management’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-33,644
Closed -$183K – 2177
2026
Q2
$183K Buy
33,644
+9,225
+38% +$38.8K ﹤0.01% 1429
2026
Q1
$75K Sell
24,419
-92,907
-79% -$285K ﹤0.01% 1450
2025
Q4
$418K Buy
117,326
+2,083
+2% +$7.72K ﹤0.01% 1216
2025
Q3
$402K Buy
+115,243
New +$395K ﹤0.01% 1235
2022
Q2
– Sell
-106,505
Closed -$759K – 2454
2022
Q1
$759K Buy
106,505
+75,805
+247% +$511K 0.01% 1308
2021
Q4
$299K Buy
+30,700
New +$273K ﹤0.01% 1657

Other funds holding STLN

ExodusPoint Capital Management's STLN Position: Q3 2026 in Review

ExodusPoint Capital Management sold out of Starling Oncology (STLN) in Q3 2026, closing a stake of 33,644 shares — an estimated $183K sold.

ExodusPoint Capital Management first reported a position in STLN in Q4 2021 and held it in 6 quarters. The position peaked at $759K in Q1 2022. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • ExodusPoint Capital Management reported no remaining Starling Oncology position as of Q3 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 33,644 Starling Oncology shares in Q3 2026, an estimated $183K.
  • ExodusPoint Capital Management first reported a position in Starling Oncology in Q4 2021 and held it in 6 quarters.
  • ExodusPoint Capital Management's Starling Oncology position peaked at $759K in Q1 2022.
  • 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.